News

News

Challenges in Antisense Oligonucleotide (ASO) PK Bioanalysis

Antisense oligonucleotides (ASOs) are a growing class of therapeutic agents that modulate gene expression and promise to treat a spectrum of disorders once considered 'undruggable'. Since their first market entry in the '90s, the FDA and EMA have approved at least nine ASO therapies for conditions…
20 May 2024

Quarterly Update: March 2024 Highlights

Spring has brought with it not only new blooms and good weather but also the most impressive quarter we have ever experienced at Nanovery. This period has been marked by incredible growth, thanks to the remarkable efforts and skills of our team. Their dedication and expert work are the driving…
29 Mar 2024

Quarterly Update: November 2023 Highlights

This November has been a busy month for Nanovery, filled with significant advancements and promising developments as we round off the year. Reflecting on our journey, we're excited to share these key highlights with our community, highlighting our relentless pursuit of innovation in biotechnology.…
4 Dec 2023

Navigating the Challenges of MicroRNA Quantification

In this short article, we will provide an overview of the needs and challenges associated with the quantification of miRNAs for expression analysis. MicroRNAs (miRNAs) play a key role in regulating protein production by binding to messenger RNA (mRNA) in the cells of humans, animals, and plants.…
17 Nov 2023

Introduction to microRNA-122

Regulating gene expression is essential to maintain the balance and functions of various systems in all living organisms. The microRNA (miRNA) molecules have emerged as significant contributors in that domain. First discovered in 1993 [1], these short, single-stranded RNA molecules (typically 21-23…
18 Oct 2023

We are attending BIOEurope 2023

We are attending #BIOEurope in Munich, Germany, on November 6-8, 2023. We look forward to meeting potential partners and investors there.
9 Aug 2023

Nanovery secures over £1.85 million for cancer diagnostic solution

For more information, please read: the full story here and here. We at Nanovery are thrilled to announce that we have successfully raised over £1.85 million in funding to further our mission of saving lives through better testing for prostate cancer. This funding round is a significant milestone…
12 Apr 2023

Nanovery Appoints Chief Executive Officer

For more information, please read: the full story at businessNEWS Nanovery appoints new CEO Mark Chadwick to lead growth and innovation in the biotech industry. Mark brings a wealth of knowledge and expertise to the company and will be responsible for leading the company through its next phase of…
28 Mar 2023

Most Popular

We are a data driven company using DNA nanotechnology and AI to scale up testing of nucleic acids for powerful insights from valuable samples.